Osteon Medical Ltd

Osteon Medical Ltd from Birmingham, UK, is a small, active company founded seven years ago. With just two employees and £157,401 in assets, it operates from a virtual address—a detail highlighted by the fact that fifty-four other companies share the same location. The company is led by a solo founder and one director, Ehsan Maneeza. It’s a regular importer, bringing in optical and medical tools and devices for a substantial 87 months, with the latest import occurring in February 2025.

The company's website paints a picture of a specialist UK SpinalOrthopaedic company partnering with innovative manufacturers to bring the latest technologies to market. Osteon Medical focuses on spinal and bone regeneration technology, offering training, biologics, and specialized support services. It appears to be a business-to-business operation, providing solutions for physicians and hospitals rather than directly selling to consumers. The website emphasizes innovation, collaboration, and value-based healthcare, suggesting a focus on high-quality products and services.

Financially, Osteon Medical Ltd presents a mixed picture. While the company’s net assets remain stable at £110,000, current assets have fallen by 21% to £160,000. Bank borrowings have decreased by 22% to £26,000, and cash reserves have dropped by 30% to £120,000. Interestingly, finished goods have increased by a significant 140% to £30,000, which could indicate increased inventory levels or a surge in demand. The number of employees has risen to three, which is a change from the previous year. Although the company is small, meeting two of three criteria for classification, the decrease in cash reserves and the rise in finished goods warrant further observation. The unaudited accounts, exempt due to its small size, rely on director-reported data.

Registered in England/Wales under the registration number 10916177, with a registered address at B6 7DG, United Kingdom, Birmingham, 133 Tame Road.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.